Defining the site of recurrent disease shortly after the completion of definitive treatment for localized prostate cancer constitutes a crucial concern as it can significantly impact subsequent therapeutic decisions and patient care. While the diagnosis of biochemical recurrence primarily relies on monitoring PSA levels and their trends, localization of recurrence requires various imaging techniques that are essential for effective disease management. Unfortunately, traditional methods like transrectal ultrasound (TRUS) and conventional imaging often exhibit limited accuracy, particularly in the early stages of local recurrence detection. In contrast, functional and molecular imaging modalities such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) offer the ability to visualize molecular and cellular processes within individual tumors. In recent times, 18F-fluorocholine PET/CT and, more recently, PSMA PET/CT have emerged as successful tools for identifying both local recurrences and distant metastases. Nevertheless, in cases where the diagnosis remains ambiguous, it becomes necessary to conduct either a biopsy of the prostatic fossa or a prostate biopsy, guided by MRI or TRUS findings, to definitively assess the presence of a local recurrence. In summary, it is highly likely that imaging techniques will see extensive utilization in the future for the early detection and precise localization of local prostate cancer recurrences before considering salvage treatment options.